The tumor suppressor function of LECT2 in human hepatocellular carcinoma makes it a potential therapeutic target

Cancer Gene Therapy

Volumn 18, Issue 6, 2011, Pages 399-406

  Ong, H T ^a   Tan, P K ^a   Wang, S M ^a   Hian Low, D T ^a   Pj Ooi, L L ^b   Hui, K M ^a  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

adenovirus mediated gene therapy; human hepatocellular carcinoma (HCC); leukocyte cell derived chemotaxin 2 (LECT2); tumor invasion and metastasis

Indexed keywords

ADENOVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER PATIENT; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LECT2 GENE; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

ADENOVIRIDAE; ANIMALS; CARCINOMA, HEPATOCELLULAR; FEMALE; GENES, TUMOR SUPPRESSOR; GENETIC VECTORS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MICE; MICE, NUDE; TRANSFECTION; TUMOR CELLS, CULTURED;

ADENOVIRIDAE; MUS MUSCULUS;

EID: 79956119644     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.5     Document Type: Article

References (41)

1. Hui KM. Human hepatocellular carcinoma: expression profiles-based molecular interpretations and clinical applica-tions. Cancer Lett 2009; 286: 96-102.
2. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
3. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Prognostic molecular markers in hepatocellular carci-noma: a systematic review. Eur J Cancer 2007; 43: 979-992. (Pubitemid 46483030)
4. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 2008; 7: 237-257. (Pubitemid 351895383)
5. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917. (Pubitemid 37518510)
6. Schiffman SC, Woodall CE, Kooby DA, Martin RC, Staley CA, Egnatashvili V et al. Factors associated with recurrence and survival following hepatectomy for large hepatocellular carci-noma: a multicenter analysis. J Surg Oncol 2010; 101: 105-110.
7. Thuerigen O, Schneeweiss A, Toedt G, Warnat P, Hahn M, Kramer H et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 2006; 24: 1839-1845. (Pubitemid 46638981)
8. Tsai TJ, Chau GY, Lui WY, Tsay SH, King KL, Loong CC et al. Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcino-ma. Surgery 2000; 127: 603-608.
9. Wang SM, Ooi LL, Hui KM. Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma. Clin Cancer Res 2007; 13: 6275-6283. (Pubitemid 350075015)
10. Zhou YM, Yang JM, Li B, Yin ZF, Xu F, Wang B et al. Risk factors for early recurrence of small hepatocellular carcinoma after curative resection. Hepatobiliary Pancreat Dis Int 2010; 9: 33-37.
11. Kameoka Y, Yamagoe S, Hatano Y, Kasama T, Suzuki K. Val58Ile polymorphism of the neutrophil chemoattractant LECT2 and rheumatoid arthritis in the Japanese population. Arthritis Rheum 2000; 43: 1419-1420. (Pubitemid 30416331)
12. Okumura A, Saito T, Otani I, Kojima K, Yamada Y, Ishida-Okawara A et al. Suppressive role of leukocyte cell-derived chemotaxin 2 in mouse anti-type II collagen antibody-induced arthritis. Arthritis Rheum 2008; 58: 413-421. (Pubitemid 351294876)
13. Ovejero C, Cavard C, Perianin A, Hakvoort T, Vermeulen J, Godard C et al. Identification of the leukocyte cell-derived chemotaxin 2 as a direct target gene of beta-catenin in the liver. Hepatology 2004; 40: 167-176. (Pubitemid 38868935)
14. Saito T, Okumura A, Watanabe H, Asano M, Ishida-Okawara A, Sakagami J et al. Increase in hepatic NKT cells in leukocyte cell-derived chemotaxin 2-deficient mice contributes to severe concanavalin A-induced hepatitis. J Immunol 2004; 173: 579-585. (Pubitemid 38797386)
15. Segawa Y, Itokazu Y, Inoue N, Saito T, Suzuki K. Possible changes in expression of chemotaxin LECT2 mRNA in mouse liver after concanavalin A-induced hepatic injury. Biol Pharm Bull 2001; 24: 425-428. (Pubitemid 32377614)
16. Uchida T, Nagai H, Gotoh K, Kanagawa H, Kouyama H, Kawanishi T et al. Expression pattern of a newly recognized protein, LECT2, in hepatocellular carcinoma and its premalignant lesion. Pathol Int 1999; 49: 147-151. (Pubitemid 29133474)
17. Yamagoe S, Yamakawa Y, Matsuo Y, Minowada J, Mizuno S, Suzuki K. Purification and primary amino acid sequence of a novel neutrophil chemotactic factor LECT2. Immunol Lett 1996; 52: 9-13. (Pubitemid 26279098)
18. Okumura A, Suzuki T, Dohmae N, Okabe T, Hashimoto Y, Nakazato K et al. Identification and assignment of three disulfide bonds in mammalian leukocyte cell-derived chemo-taxin 2 by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Biosci Trends 2009; 3: 139-143.
19. Yamagoe S, Kameoka Y, Hashimoto K, Mizuno S, Suzuki K. Molecular cloning, structural characterization, and chromosomal mapping of the human LECT2 gene. Genomics 1998; 48: 324-329. (Pubitemid 28180732)
20. Yamagoe S, Akasaka T, Uchida T, Hachiya T, Okabe T, Yamakawa Y et al. Expression of a neutrophil chemotactic protein LECT2 in human hepatocytes revealed by immuno-chemical studies using polyclonal and monoclonal antibodies to a recombinant LECT2. Biochem Biophys Res Commun 1997; 237: 116-120. (Pubitemid 27390335)
21. Yamagoe S, Mizuno S, Suzuki K. Molecular cloning of human and bovine LECT2 having a neutrophil chemotactic activity and its specific expression in the liver. Biochim Biophys Acta 1998; 1396: 105-113. (Pubitemid 28131450)
22. Benson MD, James S, Scott K, Liepnieks JJ, Kluve-Beckerman B. Leukocyte chemotactic factor 2: a novel renal amyloid protein. Kidney Int 2008; 74: 218-222. (Pubitemid 351915083)
23. Larsen CP, Walker PD, Weiss DT, Solomon A. Prevalence and morphology of leukocyte chemotactic factor 2-associated amyloid in renal biopsies. Kidney Int 2010; 77: 816-819.
24. Linn YC, Wang SM, Hui KM. Comparative gene expression profiling of cytokine-induced killer cells in response to acute myeloid leukemic and acute lymphoblastic leukemic stimu¬lators using oligonucleotide arrays. Exp Hematol 2005; 33: 671-681. (Pubitemid 40725833)
25. Tan MG, Ooi LL, Aw SE, Hui KM. Cloning and identification of hepatocellular carcinoma down-regulated mitochondrial carrier protein, a novel liver-specific uncou-pling protein. J Biol Chem 2004; 279: 45235-45244. (Pubitemid 39430939)
26. Russell WC. Update on adenovirus and its vectors. J Gen Virol 2000; 81(Part 11): 2573-2604.
27. Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, Mehtali M. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 1996; 70: 4805-4810. (Pubitemid 26187479)
28. Michou AI, Lehrmann H, Saltik M, Cotten M. Mutational analysis of the avian adenovirus CELO, which provides a basis for gene delivery vectors. J Virol 1999; 73: 1399-1410. (Pubitemid 29036795)
29. Cotten M, Baker A, Birnstiel ML, Zatloukal K, Wagner E. Adenovirus polylysine DNA conjugates. In: Dracopoli NC, Haines JL, Korf BR, Moir DT, Morton CC, Seidman CE et al. (eds). Current Protocols in Human Genetics. Wiley: New York, 1996. pp 12.13.11-12.13.33.
30. Lemay P, Boudin ML, Milleville M, Boulanger P. Human adenovirus type 2 protein IIIa. I. Purification and characterization. Virology 1980; 101: 131-143. (Pubitemid 10164346)
31. Portolani N, Ronconi M, Ghidoni S, Gaverini G, Coniglio A, Tiberio GA et al. Early and long-term prognostic factors after liver resection for HCC. Chir Ital 1999; 51: 335-343.
32. Nagai H, Hamada T, Uchida T, Yamagoe S, Suzuki K. Systemic expression of a newly recognized protein, LECT2, in the human body. Pathol Int 1998; 48: 882-886. (Pubitemid 28512078)
33. Ohtomi M, Nagai H, Ohtake H, Uchida T, Suzuki K. Dynamic change in expression of LECT2 during liver regeneration after partial hepatectomy in mice. Biomed Res 2007; 28: 247-253. (Pubitemid 350268136)
34. Sato Y, Watanabe H, Kameyama H, Kobayashi T, Yamamoto S, Takeishi T et al. Serum LECT2 level as a prognostic indicator in acute liver failure. Transplant Proc 2004; 36: 2359-2361. (Pubitemid 39550844)
35. Koshimizu Y, Ohtomi M. Regulation of neurite extension by expression of LECT2 and neurotrophins based on findings in LECT2-knockout mice. Brain Res 2010; 1311: 1-11.
36. Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA micro-array: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 2001; 61: 2129-2137. (Pubitemid 32692038)
37. Phesse TJ, Parry L, Reed KR, Ewan KB, Dale TC, Sansom OJ et al. Deficiency of Mbd2 attenuates Wnt signaling. Mol Cell Biol 2008; 28: 6094-6103.
38. Thompson MD, Monga SP. WNT/beta-catenin signaling in liver health and disease. Hepatology 2007; 45: 1298-1305. (Pubitemid 46775794)
39. Wodarz A, Nusse R. Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 1998; 14: 59-88. (Pubitemid 29001449)
40. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 2008; 27: 6920-6929.
41. Ji H, Wang J, Nika H, Hawke D, Keezer S, Ge Q et al. EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin. Mol Cell 2009; 36: 547-559.